

NHS Grampian Formulary Group Decisions for SMC advice published April 2021 to March 2022



This document summarises the decisions of the NHS Grampian Formulary Group for Scottish Medicines Consortium (SMC) advice published April 2021 to March 2022.

For the latest Formulary Group decisions see the [Grampian Area Formulary website](#).

November 2025

Image courtesy of Baitong333 - image ID: 100128772/ [FreeDigitalPhotos.net](#)

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
5-aminolevulinic acid 8mg medicated plaster (Alacare®)	2353	Single use treatment of adults with mild actinic keratoses lesions with a maximum diameter of 1.8cm on the face and scalp (hairless areas).	Routinely available in line with national guidance, SMC 2353 https://www.scottishmedicines.org.uk/media/6028/5-aminolevulinic-acid-alacare-abbreviated-final-may-2021-for-website.pdf Updates decision 15/06/21	17/05/2022
acalabrutinib 100mg hard capsules (Calquence®)	2346	As monotherapy or in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). SMC restriction: as monotherapy for the treatment of adult patients with previously untreated CLL who have a 17p deletion or TP53 mutation and in whom chemo-immunotherapy is unsuitable.	Routinely available in line with national guidance, SMC 2346 https://www.scottishmedicines.org.uk/media/5875/acalabrutinib-calquence-2346-abbreviated-final-march-2021-for-website.pdf Acalabrutinib capsules replaced by tablets - see FG meeting 19/09/2023 Updates decision 20/04/21	15/06/2021
acalabrutinib 100mg hard capsules (Calquence®)	2347	As monotherapy or in combination with obinutuzumab for the treatment of adults with previously untreated chronic lymphocytic leukaemia (CLL). SMC restriction: as monotherapy for the treatment of adults with previously untreated CLL without a 17p deletion or TP53 mutation and who are ineligible for fludarabine, cyclophosphamide and rituximab (FCR) therapy.	Routinely available in line with national guidance, SMC 2347 https://www.scottishmedicines.org.uk/media/6029/acalabrutinib-calquence-final-may-2021-for-website.pdf Acalabrutinib capsules replaced by tablets - see FG meeting 19/09/2023	15/06/2021
acalabrutinib 100mg hard capsules (Calquence®)	2348	As monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. SMC restriction: for adults with relapsed/refractory CLL who have had at least one previous therapy, in whom chemo-immunotherapy is unsuitable.	Routinely available in line with national guidance, SMC 2348 https://www.scottishmedicines.org.uk/media/5876/acalabrutinib-calquence-2348-abbreviated-final-march-2021-for-website.pdf Acalabrutinib capsules replaced by tablets - see FG meeting 19/09/2023 Updates decision 20/04/21	15/06/2021

NHS Grampian Formulary Group Decisions for SMC advice published April 2021 to March 2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
amikacin liposomal nebuliser dispersion 590mg (Arikayce®)	2432	Treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis. Consideration should be given to official guidance on the appropriate use of antibacterial agents.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/12/2021
anakinra 100mg/0.67mL solution for injection in prefilled syringe (150mg/mL) (Kineret®)	2449	Treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate.	Not routinely available as not recommended for use in NHS Scotland, SMC 2449 https://www.scottishmedicines.org.uk/media/6540/anakinra-kineret-non-sub-final-november-2021-for-website.pdf	21/12/2021
asfotase alfa 40mg/mL, 100mg/mL solution for injection (Strensiq®)	2433	Long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease.	Not routinely available as not recommended for use in NHS Scotland, SMC 2433 https://www.scottishmedicines.org.uk/media/6427/asfotase-alfa-strensiq-non-sub-final-october-2021-for-website.pdf	16/11/2021
Atectura Breezhaler® 125micrograms/62.5micrograms, 125micrograms/127.5micrograms, 125 micrograms/260micrograms (indacaterol/mometasone furoate)	2356	As a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short-acting beta2-agonists.	Not routinely available as there is a local preference for alternative medicines	18/05/2021
atezolizumab 1,200mg concentrate for solution for infusion (Tecentriq®)	2349	In combination with bevacizumab for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.	Routinely available in line with national guidance, SMC 2349 https://www.scottishmedicines.org.uk/media/6103/atezolizumab-tecentriq-final-june-2021-for-website.pdf Updates decision 20/07/21	21/09/2021

NHS Grampian Formulary Group Decisions for SMC advice published April 2021 to March 2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
atezolizumab 840mg, 1,200mg concentrate for solution for infusion (Tecentriq®)	2379	As monotherapy for the first-line treatment of adult patients with metastatic non small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression $\geq 50\%$ tumour cells (TC) or $\geq 10\%$ tumour-infiltrating immune cells (IC) and who do not have epidermal growth factor receptor (EGFR) mutant or anaplastic lymphoma kinase (ALK)-positive NSCLC.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	16/11/2021
autologous anti-CD19-transduced CD3+ cells (KTE X19) 0.4 to 2×10^8 cells dispersion for infusion (Tecartus®)	2351	For the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton's tyrosine kinase (BTK) inhibitor.	Routinely available in line with national guidance, on an interim basis subject to ongoing evaluation and future reassessment, SMC 2351 https://www.scottishmedicines.org.uk/media/6180/autologous-tecartus-final-july-2021-for-website.pdf Updates decision 17/08/21	20/08/2024
avapritinib 100mg, 200mg, 300mg film-coated tablets (Ayvakyt®)	2424	As monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation.	Not routinely available as not recommended for use in NHS Scotland, SMC 2424 https://www.scottishmedicines.org.uk/media/6329/avapritinib-ayvakyt-non-submission-final-sept-2021-for-website.pdf	19/10/2021
avatrombopag 20mg film-coated tablets (Doptelet®)	2345	For the treatment of primary chronic immune thrombocytopenia (ITP) in adults who are refractory to other treatments (e.g. corticosteroids or immunoglobulins). SMC restriction: to use in patients with severe symptomatic ITP or a high risk of bleeding.	Routinely available in line with national guidance, SMC 2345 https://www.scottishmedicines.org.uk/media/6181/avatrombopag-doptelet-final-july-2021-for-website.pdf Updates decision 17/08/21	21/12/2021
avelumab 20mg/mL concentrate for solution for infusion (Bavencio®)	2359	As monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are progression-free following platinum-based chemotherapy.	Routinely available in line with national guidance, SMC 2359 https://www.scottishmedicines.org.uk/media/6187/avelumab-bavencio-final-july-2021-amended-050821-for-website.pdf Updates decision 17/08/21	16/11/2021

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
baricitinib 2mg, 4mg film-coated tablets (Olumiant®)	2337	<p>Treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.</p> <p>SMC restriction: treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy who have failed at least one current systemic immunosuppressant due to intolerance, contraindication or inadequate disease control.</p>	<p>Routinely available in line with national guidance, SMC 2337</p> <p>https://www.scottishmedicines.org.uk/media/6030/baricitinib-olumiant-final-may-2021-for-website.pdf</p> <p>baricitinib Olumiant® brand tablets replaced by baricitinib Lilly - see FG meeting 19/11/2024</p> <p>Updates decision 15/06/21</p>	18/01/2022
bempedoic acid 180mg film-coated tablets (Nilemdo®)	2363	<p>In adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:</p> <ul style="list-style-type: none"> - in combination with a statin, or a statin with other lipid-lowering therapies in patients unable to reach low density lipoprotein cholesterol (LDL-C) goals with the maximum tolerated dose of a statin or - alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contra-indicated. <p>SMC restriction: for use in combination with ezetimibe in patients who are:</p> <ul style="list-style-type: none"> - statin intolerant or for whom a statin is contra-indicated and - where ezetimibe alone does not appropriately control LDL-C and - where proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors are not appropriate 	<p>Routinely available in line with local guidance, Updates decision 20/07/21</p>	19/10/2021
berotralstat 150mg hard capsules (Orladeyo®)	2405	<p>Routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older.</p> <p>SMC restriction: patients who experience \geq two clinically significant attacks per month.</p>	<p>Routinely available in line with national guidance, SMC 2405</p> <p>https://www.scottishmedicines.org.uk/media/6734/berotralstat-oraldeyo-final-feb-2022-amended-220222-for-website.pdf</p> <p>Updates decision 15/03/22</p>	19/04/2022

NHS Grampian Formulary Group Decisions for SMC advice published April 2021 to March 2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
Bevespi Aerosphere® 7.2micrograms/5micrograms pressurised inhalation, suspension (glycopyrronium/formoterol fumarate dihydrate)	2377	Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.	Not routinely available as not recommended for use in NHS Scotland, SMC 2377 https://www.scottishmedicines.org.uk/media/5938/glycopyrronium-bevespi-aerosphere-non-sub-final-april-2021docx-for-website.pdf	18/05/2021
bimekizumab 160mg solution for injection in pre-filled syringe, pre-filled pen (Bimzelx®)	2410	Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. SMC restriction: for patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these treatments.	Decision deferred to future meeting, Updates decision 16/11/21	20/05/2025
blinatumomab 38.5micrograms powder for concentrate and solution for infusion (Blincyto®)	2468	As monotherapy for the treatment of adults with CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL).	Not routinely available as not recommended for use in NHS Scotland, SMC 2468 https://www.scottishmedicines.org.uk/media/6736/blinatumomab-blincyto-non-sub-final-feb-2022-for-website.pdf	15/03/2022
budesonide 9mg prolonged release tablet (Cortiment®)	2448	Induction of remission in patients with active microscopic colitis.	Routinely available in line with national guidance, SMC 2448 https://www.scottishmedicines.org.uk/media/6584/budesonide-cortiment-abbreviated-final-dec-2021docx-for-website.pdf Updates decision 18/01/22	19/04/2022
buprenorphine 74.2mg implant (Sixmo®)	2372	For substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment.	Not routinely available as there is a local preference for alternative medicines Updates decision 21/12/21	16/01/2024

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
cabotegravir 30mg film-coated tablets, 600mg prolonged-release suspension for injection (Vocabria®)	2376	In combination with rilpivirine prolonged-release injection, for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class.	Not routinely available as local implementation plans are being developed. Updates decision 19/10/21	21/12/2021
cabozantinib 20mg, 40mg, 60mg film-coated tablets (Cabometyx®)	2386	In combination with nivolumab for the first-line treatment of advanced renal cell carcinoma in adults.	Routinely available in line with national guidance, SMC 2386 https://scottishmedicines.org.uk/media/6332/cabozantinib-cabometyx-abbreviated-final-sept-2021-for-website.pdf cabozantinib Cabometyx® brand tablets replaced by Cabozantinib Ipsen - see FG meeting 19/11/2024 Updates decision 19/10/21	19/11/2024
cannabidiol 100mg/mL oral solution (Epidyolex®)	2402	For use as adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC) for patients 2 years of age and older.	Routinely available in line with national guidance, SMC 2402 https://www.scottishmedicines.org.uk/media/6670/cannabidiol-epidyolex-final-jan-2022-amended-200122-for-website.pdf Updates decision 15/02/22	20/12/2022
cenobamate 12.5mg, 25mg, 50mg, 100mg, 150mg, 200mg film-coated tablets (Ontozry®)	2408	For the adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite treatment with at least 2 anti-epileptic medicinal products. SMC restriction: in patients with drug-resistant epilepsy as a second-line adjunctive anti-seizure medicine, after the failure of the first adjunctive anti-seizure medicine.	Routinely available in line with national guidance, SMC 2408 https://www.scottishmedicines.org.uk/media/6671/cenobamate-ontozry-final-jan-2022-amended-180122-for-website.pdf Updates decision 15/02/22	16/08/2022

NHS Grampian Formulary Group Decisions for SMC advice published April 2021 to March 2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
chlormethine hydrochloride 160micrograms/g gel (Ledaga®)	2318	For the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients.	Routinely available in line with national guidance, SMC 2318 https://www.scottishmedicines.org.uk/media/5936/chlormethine-hydrochloride-ledaga-final-april-2021docx-for-website.pdf Updates decision 18/05/21	20/07/2021
chlorprocaine hydrochloride 10mg/mL solution for injection (Ampres®)	2373	Spinal anaesthesia in adults where the planned surgical procedure should not exceed 40 minutes. SMC restriction: for use in day-case anaesthetic pathways.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	19/10/2021
dapagliflozin 10mg film coated tablets (Forxiga®)	2322	In adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.	Routinely available in line with national guidance, SMC 2322 https://www.scottishmedicines.org.uk/media/5877/dapagliflozin-forxiga-final-march-2021-for-website.pdf Updates decision 20/04/21	20/07/2021
daratumumab 1,800mg solution for injection (Darzalex®)	2469	In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide-refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy.	Not routinely available as not recommended for use in NHS Scotland, SMC 2469 https://www.scottishmedicines.org.uk/media/6737/daratumumab-darzalex-non-sub-final-feb-2022-for-website.pdf	15/03/2022
delafloxacin 300mg powder for concentrate for solution for infusion, 450mg tablets (Quofenix®)	2393	For the treatment of community-acquired pneumonia (CAP) in adults when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections. Consideration should be given to official guidance on the appropriate use of antibacterial agents.	Not routinely available as not recommended for use in NHS Scotland, SMC 2393 https://www.scottishmedicines.org.uk/media/6105/delafloxacin-quofenix-non-sub-final-june-2021-for-website.pdf	20/07/2021

NHS Grampian Formulary Group Decisions for SMC advice published April 2021 to March 2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
diroximel fumarate 231mg gastro-resistant hard capsules (Vumerity®)	2444	Treatment of adult patients with relapsing remitting multiple sclerosis.	Routinely available in line with national guidance, SMC 2444 https://www.scottishmedicines.org.uk/media/6672/diroxime-l-fumarate-vumerity-abbreviated-final-jan-2022-for-website.pdf Updates decision 15/02/22	18/04/2023
dostarlimab 500mg concentrate for solution for infusion (Jemperli®)	2404	As monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen.	Routinely available in line with national guidance, on an interim basis subject to ongoing evaluation and future reassessment, SMC 2404 https://www.scottishmedicines.org.uk/media/6727/dostarlimab-jemperli-final-december-2021-for-website.pdf Updates decision 15/03/22	21/06/2022
dupilumab 200mg, 300mg solution for injection in pre-filled syringe, pre-filled pen (Dupixent®)	2317	In adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment. SMC restriction: for the treatment of patients with blood eosinophils ≥ 150 cells/microlitre and FeNO ≥ 25 parts per billion, and ≥ 4 exacerbations in the preceding year, who have previously received biologic treatment with anti-IgE or anti-IL-5 therapies.	Routinely available in line with national guidance, SMC 2317 https://www.scottishmedicines.org.uk/media/5871/dupilumab-dupixent-final-march-2021-amended-190321-for-website.pdf Updates decision 20/04/21	20/07/2021
eculizumab 300mg concentrate for solution for infusion (Soliris®)	2456	Treatment of adults with neuromyelitis optica spectrum disorder in patients who are anti-aquaporin-4 antibody-positive with a relapsing course of the disease.	Not routinely available as not recommended for use in NHS Scotland, SMC 2456 https://www.scottishmedicines.org.uk/media/6585/eculizumab-soliris-non-sub-final-december-2021docx-for-website.pdf	18/01/2022

NHS Grampian Formulary Group Decisions for SMC advice published April 2021 to March 2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
elotuzumab 300mg, 400mg powder for concentrate for solution for infusion (Empliciti®)	2407	In combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.	Not routinely available as not recommended for use in NHS Scotland, SMC 2407 https://www.scottishmedicines.org.uk/media/6182/elotuzumab-empliciti-non-sub-final-july-2021-for-website.pdf	17/08/2021
empagliflozin 10mg film-coated tablets (Jardiance®)	2396	In adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. Restriction: start treatment on the advice of a heart failure specialist/cardiologist.	Routinely available in line with local guidance	19/10/2021
encorafenib 50mg, 75mg hard capsules (Braftovi®)	2312	In combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/05/2021
Energair Breezhaler® 114micrograms/46micrograms/ 136micrograms (indacaterol/glycopyrronium/ mometasone furoate)	2355	As a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.	Not routinely available as there is a local preference for alternative medicines	18/05/2021
enzalutamide 40mg film-coated tablets (Xtandi®)	2400	Treatment of adults with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).	Routinely available in line with national guidance, SMC 2400 https://www.scottishmedicines.org.uk/media/6666/enzalutamide-xtandi-final-jan-2022-for-website.pdf Updates decision 15/02/22	21/06/2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
filgotinib 100mg, 200mg film-coated tablets (Jyseleca®)	2365	<p>For the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti rheumatic drugs (DMARDs). Filgotinib may be used as monotherapy or in combination with methotrexate (MTX).</p> <p>SMC restriction: in patients with severe disease (a disease activity score [DAS28] greater than 5.1) that has not responded to intensive therapy with a combination of conventional DMARDs and in patients with severe disease inadequately controlled by a TNF antagonist in whom rituximab is not appropriate.</p>	<p>Routinely available in line with national guidance, SMC 2365</p> <p>https://www.scottishmedicines.org.uk/media/6244/filgotinib-jyseleca-final-august-2021-for-website.pdf</p> <p>Updates decision 21/09/21</p>	19/10/2021
fostemsavir 600mg prolonged-release tablets (Rukobia®)	2389	<p>In combination with other antiretrovirals for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.</p>	<p>Not routinely available as not recommended for use in NHS Scotland, SMC 2389</p> <p>https://www.scottishmedicines.org.uk/media/6106/fostemsavir-rukobia-non-sub-final-june-2021-for-website.pdf</p>	20/07/2021
galcanezumab 120mg solution for injection in pre-filled pen (Emgality®)	2313	<p>Prophylaxis of migraine in adults who have at least 4 migraine days per month.</p> <p>SMC restriction: for the treatment of patients with chronic and episodic migraine who have had prior failure on three or more migraine preventive treatments.</p>	<p>Not routinely available as there is a local preference for alternative medicines, ADVICE ARCHIVED, replaced by FG advice published 03/03/2025 (FG meeting 18/02/2025).</p> <p>Updates decision 20/04/21</p>	20/06/2023
givosiran 189mg/mL solution for injection (Givlaari®)	2470	<p>Treatment of acute hepatic porphyria in adults and adolescents aged 12 years and older.</p>	<p>Not routinely available as not recommended for use in NHS Scotland, SMC 2470</p> <p>https://www.scottishmedicines.org.uk/media/6728/givosiran-givlaari-non-sub-final-feb-2022-for-website.pdf</p>	15/03/2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
guselkumab 100mg solution for injection in pre-filled pen (Tremfya®)	2360	<p>Alone or in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy.</p> <p>SMC restriction: (i) patients whose disease has not responded adequately or who have been intolerant to two previous conventional disease-modifying antirheumatic drug (DMARD) therapies but have not received biologic DMARD therapy (biologic-naïve population); (ii) patients whose disease has not responded adequately to conventional DMARDs and one or more tumour necrosis factor (TNF) inhibitors (biologic-experienced population); and (iii) patients in whom TNF inhibitors are contraindicated or not tolerated.</p>	<p>Routinely available in line with national guidance, SMC 2360 https://www.scottishmedicines.org.uk/media/6176/guselkumab-tremfya-final-july-2021-for-website.pdf Updates decision 17/08/21</p>	15/03/2022
hydrocortisone modified-release 5mg, 10mg, 20mg hard capsules (Efmody®)	2414	Treatment of congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over and adults.	<p>Not routinely available as not recommended for use in NHS Scotland, SMC 2414 https://www.scottishmedicines.org.uk/media/6729/hydrocortisone-modified-release-efmody-final-feb-2022-for-website.pdf</p>	15/03/2022
ibrutinib 140mg, 280mg, 420mg film-coated tablets (Imbruvica®)	2387	<p>As a single agent for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemo-immunotherapy.</p> <p>SMC restriction: for use in patients who have received at least one prior therapy.</p>	<p>Routinely available in line with national guidance, SMC 2387 https://www.scottishmedicines.org.uk/media/6542/ibrutinib-imbruvica-final-november-2021-for-website.pdf Updates decision 21/12/21</p>	15/02/2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
inclisiran 284mg solution for injection in pre-filled syringe (Leqvio®)	2358	<p>For adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:</p> <ul style="list-style-type: none"> - in combination with a statin or statin with other lipid lowering therapies in patients who are unable to reach LDL-C goals with the maximum tolerated dose of a statin, or - alone or in combination with other lipid lowering therapies in patients who are statin intolerant, or for whom a statin is contraindicated. <p>SMC restriction: for specialist use only in patients at high cardiovascular risk as follows:</p> <ul style="list-style-type: none"> - patients with heterozygous familial hypercholesterolaemia (HeFH) and LDL-C ≥ 5.0mmol/L, for primary prevention of cardiovascular events or, - patients with HeFH and LDL-C ≥ 3.5mmol/L, for secondary prevention of cardiovascular events or, - patients with high risk due to previous cardiovascular events and LDL-C ≥ 4.0mmol/L or, - patients with recurrent/polyvascular disease and LDL-C ≥ 3.5mmol/L. 	<p>Routinely available in line with national guidance, SMC 2358</p> <p>https://www.scottishmedicines.org.uk/media/6188/inclisiran-leqvio-final-july-2021-amended-050821-for-website.pdf</p> <p>Updates decision 17/08/21</p>	19/10/2021
isatuximab 20mg/mL concentrate for solution for infusion (Sarclisa®)	2423	<p>In combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.</p>	<p>Not routinely available as not recommended for use in NHS Scotland, SMC 2423</p> <p>https://www.scottishmedicines.org.uk/media/6335/isatuximab-sarclisa-non-submission-final-sept-2021-for-website.pdf</p>	19/10/2021

NHS Grampian Formulary Group Decisions for SMC advice published April 2021 to March 2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
isatuximab 20mg/mL concentrate for solution for infusion (Sarclisa®)	2303	In combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (PI) and have demonstrated disease progression on the last therapy. SMC restriction: patients receiving fourth-line therapy	Routinely available in line with national guidance, SMC 2303 https://www.scottishmedicines.org.uk/media/5873/isatuximab-sarclisa-final-march-2021-amended-060421-for-website.pdf Updates decision 20/04/21	20/07/2021
Lonsurf® 15mg/6.14mg, 20mg/8.19mg film-coated tablets (trifluridine/tipiracil)	2329	As monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with two prior systemic treatment regimens for advanced disease. SMC restriction: for use as third line treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction.	Routinely available in line with national guidance, SMC 2329 https://www.scottishmedicines.org.uk/media/6026/trifluridinetipiracil-lonsurf-final-may-2021-for-website.pdf Updates decision 15/06/21	21/09/2021
lorlatinib 25mg, 100mg film-coated tablets (Lorviqua®)	2415	As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.	Not routinely available as there is a local preference for alternative medicines Updates decision 15/03/22	15/08/2023
midazolam 2mg/mL oral solution in single-dose container (Ozalin®)	2392	In children from 6 months to 17 years old, for moderate sedation before a therapeutic or diagnostic procedure or as premedication before anaesthesia.	Not routinely available as there is a local preference for alternative medicines Updates decision 19/10/21	21/12/2021

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
mogamulizumab 4mg/mL concentrate for solution for infusion (Poteligeo®)	2336	For the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy. SMC restriction: for the treatment of patients with advanced MF or SS (stage ≥IIB MF and all SS) following at least one prior systemic therapy, who are clinically ineligible for or refractory to treatment with brentuximab vedotin.	Routinely available in line with national guidance, SMC 2336 https://www.scottishmedicines.org.uk/media/6023/mogamulizumab-poteligeo-final-may-2021-amended-240521-for-website.pdf Updates decision 15/06/21	17/08/2021
nintedanib 100mg, 150mg soft capsules (Ofev®)	2331	In adults for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype other than idiopathic pulmonary fibrosis (IPF).	Routinely available in line with national guidance, SMC 2331 https://www.scottishmedicines.org.uk/media/6024/nintedanib-ofev-final-may-2021-for-website.pdf Updates decision 15/06/21	16/11/2021
niraparib tosylate monohydrate 100mg hard capsules (Zejula®)	2338	As monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III or IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.	Routinely available in line with national guidance, SMC 2338 https://www.scottishmedicines.org.uk/media/5941/niraparib-zejula-final-april-2020-amended-4521docx-for-website.pdf Niraparib capsules replaced by tablets - see FG meeting 16/01/2024 Updates decision 18/05/21	17/08/2021
nitisinone 2mg, 5mg, 10mg, 20mg hard capsules, 4mg/mL oral suspension (Orfadin®)	2450	Treatment of adult patients with alkaptonuria (AKU).	Not routinely available as not recommended for use in NHS Scotland, SMC 2450 https://www.scottishmedicines.org.uk/media/6543/nitisinone-orfadin-non-sub-final-november-2021-for-website.pdf	21/12/2021
nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®)	2362	As monotherapy for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy.	Routinely available in line with national guidance, SMC 2362 https://www.scottishmedicines.org.uk/media/6177/nivolumab-opdivo-final-july-2021-for-website.pdf Updates decision 17/08/21	16/11/2021

NHS Grampian Formulary Group Decisions for SMC advice published April 2021 to March 2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®)	2385	In combination with ipilimumab for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM).	Routinely available in line with national guidance, SMC 2385 https://www.scottishmedicines.org.uk/media/6667/nivolumab-opdivo-final-jan-2022-for-website.pdf Updates decision 15/02/22	15/11/2022
nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®)	2394	In combination with ipilimumab for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.	Not routinely available as there is a local preference for alternative medicines Updates decision 21/12/21	15/03/2022
nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®)	2397	In combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.	Not routinely available as not recommended for use in NHS Scotland, SMC 2397 https://www.scottishmedicines.org.uk/media/6586/nivolumab-opdivo-final-december-2021docx-for-website.pdf	18/01/2022
Nustendi® 180mg/10mg film coated tablets (bempedoic acid/ezetimibe)	2406	For primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet for use in adults who are: - statin intolerant or for whom a statin is contra-indicated and - where ezetimibe alone does not appropriately control LDL-C and - where proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors or inclisiran are not appropriate	Routinely available in line with local guidance	19/10/2021

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
ofatumumab 20mg/0.4mL solution for injection in pre-filled syringe/pen (Kesimpta®)	2357	For the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. SMC restriction: treatment of relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.	Routinely available in line with national guidance, SMC 2357 https://www.scottishmedicines.org.uk/media/6108/ofatumumab-kesimpta-final-june-2021-for-website.pdf Updates decision 20/07/21	21/09/2021
olaparib 100mg, 150mg film-coated tablets (Lynparza®)	2366	As monotherapy for the treatment of adult patients with metastatic castration resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.	Routinely available in line with national guidance, SMC 2366 https://www.scottishmedicines.org.uk/media/6338/olaparib-lynparza-final-september-2021-for-website.pdf Updates decision 19/10/21	21/02/2023
olaparib 100mg, 150mg film-coated tablets (Lynparza®)	2367	As monotherapy maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. SMC restriction: patients with BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.	Routinely available in line with national guidance, SMC 2367 https://www.scottishmedicines.org.uk/media/6178/olaparib-lynparza-abbreviated-final-july-2021-for-website.pdf Updates decision 17/08/21	17/05/2022
olaparib 100mg, 150mg film-coated tablets (Lynparza®)	2368	In combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.	Routinely available in line with national guidance, SMC 2368 https://www.scottishmedicines.org.uk/medicines-advice/olaparib-lynparza-full-smc2368/ Updates decision 21/12/21	20/12/2022

NHS Grampian Formulary Group Decisions for SMC advice published April 2021 to March 2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
olaparib 100mg, 150mg film-coated tablets (Lynparza®)	2435	As monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.	Not routinely available as not recommended for use in NHS Scotland, SMC 2435 https://www.scottishmedicines.org.uk/media/6434/olaprib-lynparza-non-sub-final-october-2021-for-website.pdf	16/11/2021
olaparib 100mg, 150mg film-coated tablets (Lynparza®)	2436	As monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments.	Not routinely available as not recommended for use in NHS Scotland, SMC 2436 https://www.scottishmedicines.org.uk/media/6433/olaparib-lynparza-non-sub-final-oct-2021-for-website.pdf	16/11/2021
opicapone 50mg hard capsules (Ongentys®)	2430	As adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.	Routinely available in line with local guidance, Updates decision 18/01/22	17/01/2023
osimertinib 40mg, 80mg film-coated tablets (Tagrisso®)	2382	As monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.	Routinely available in line with national guidance, SMC 2382 https://www.scottishmedicines.org.uk/media/6588/osimertinib-tagrisso-resub-final-december-2021docx-for-website.pdf Updates decision 18/01/22	15/03/2022
osimertinib 40mg, 80mg film-coated tablets (Tagrisso®)	2383	As monotherapy for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIa non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions (Ex19del) or exon 21 (L858R) substitution mutations. SMC restriction: treatment with osimertinib is subject to a three-year clinical stopping rule.	Routinely available in line with national guidance, SMC 2383 https://www.scottishmedicines.org.uk/media/6422/osimertinib-tagrisso-final-october-2021-for-website.pdf Updates decision 16/11/21	15/03/2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
patiomer sorbitex calcium 8.4g, 16.8g powder for oral suspension (Veltassa®)	2381	For the treatment of hyperkalaemia in adults. SMC restriction: patients with hyperkalaemia (defined as a serum potassium of >6.0mmol/L) with chronic kidney disease (CKD) stage 3b to 5 and/or heart failure, who would otherwise need to down-titrate or discontinue their renin-angiotensin-aldosterone system inhibitor (RAASi) therapy to maintain a clinically acceptable serum potassium level (normokalaemia).	Not routinely available as there is a local preference for alternative medicines Updates decision 17/08/21	20/02/2024
pembrolizumab 25mg/mL concentrate for solution for infusion (Keytruda®)	2375	As monotherapy for the first-line treatment of metastatic microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in adults. SMC restriction: treatment with pembrolizumab is subject to a two-year clinical stopping rule.	Routinely available in line with national guidance, SMC 2375 https://www.scottishmedicines.org.uk/media/6246/pembrolizumab-keytruda-final-august-2021-for-website.pdf Updates decision 21/09/21	16/11/2021
pembrolizumab 25mg/mL concentrate for solution for infusion (Keytruda®)	2380	As monotherapy for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option. SMC restriction: treatment with pembrolizumab is subject to a two-year clinical stopping rule.	Routinely available in line with national guidance, SMC 2380 https://www.scottishmedicines.org.uk/media/6423/pembrolizumab-keytruda-final-october-2021-for-website.pdf Updates decision 16/11/21	18/01/2022
pemigatinib 4.5mg, 9mg, 13.5mg tablets (Pemazyre®)	2399	For the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.	Routinely available in line with national guidance, SMC 2399 https://www.scottishmedicines.org.uk/media/6668/pemigatinib-pemazyre-final-jan-2022-for-website.pdf Updates decision 15/02/22	16/01/2024

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
Phesgo® 600mg/600mg, 1,200mg/600mg solution for injection (pertuzumab/trastuzumab)	2364	<p><u>Early breast cancer (EBC)</u> In combination with chemotherapy in: - the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence - the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence</p> <p><u>Metastatic breast cancer (MBC)</u> In combination with docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. SMC restriction: restricted to use in line with previous SMC advice for pertuzumab and trastuzumab (see SMC 2284; SMC2120; SMC 2119; SMC 928/13; SMC 278/06)</p>	Routinely available in line with national guidance, SMC 2364 https://www.scottishmedicines.org.uk/media/6111/pertuzumab-plus-trastuzumab-phesgo-abbreviated-final-june-2021-amended-for-website.pdf Updates decision 20/07/21	21/12/2021
ponesimod titration pack, 20mg film-coated tablets (Ponvory®)	2384	<p>The treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. SMC restriction: adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features, suitable for or requesting an oral treatment.</p>	Routinely available in line with national guidance, SMC 2384 https://www.scottishmedicines.org.uk/media/9446/ponesimod-ponvory-abbreviated-final-october-2021-for-website.pdf Updates decision 16/11/21	18/01/2022
ramucirumab 10mg/mL concentrate for solution for infusion (Cyramza®)	2291	<p>In combination with erlotinib for the first-line treatment of adult patients with metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations.</p>	Not routinely available as not recommended for use in NHS Scotland, SMC 2291 https://www.scottishmedicines.org.uk/media/6025/ramucirumab-cyramza-non-sub-final-may-2021-for-website.pdf	15/06/2021

NHS Grampian Formulary Group Decisions for SMC advice published April 2021 to March 2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
ravulizumab 300mg/30mL, 300mg/3mL, 1,100mg/11mL concentrate for solution for infusion (Ultomiris®)	2330	For the treatment of patients with a body weight of 10kg or above with atypical haemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab. SMC restriction: under the advice of the national renal complement therapeutics service.	Routinely available in line with national guidance, SMC 2330 https://www.scottishmedicines.org.uk/media/5942/ravulizumab-ultomiris-ahus-final-april-2021docx-for-website.pdf	18/05/2021
Recarbrio® 500mg/500mg/250mg powder for solution for infusion (imipenem/cilastatin/relabactam)	2390	For the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.	Not routinely available as not recommended for use in NHS Scotland, SMC 2390 https://www.scottishmedicines.org.uk/media/6107/imipenem-cilastatin-relabactam-recarbrio-non-sub-final-june-2021-for-website.pdf	20/07/2021
risdiplam 0.75mg/mL powder for oral solution (Evrysdi®)	2401	For the treatment of 5q spinal muscular atrophy (SMA) in patients 2 months of age and older, with a clinical diagnosis of SMA type 1, type 2 or type 3 or with one to four SMN2 [survival of motor neuron 2] copies.	Routinely available in line with national guidance, SMC 2401 https://www.scottishmedicines.org.uk/media/6976/risdiplam-evrysdi-final-jan-2022-amended-040722-for-website.pdf Updates decision 15/02/22	16/08/2022
Ryaltris® 600 micrograms/25 micrograms per actuation nasal spray (olopatadine hydrochloride/mometasone furoate monohydrate)	2418	In adults and adolescents 12 years of age and older for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis. SMC restriction: for use where monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.	Not routinely available as there is a local preference for alternative medicines	21/12/2021
sacituzumab govitecan 180mg powder for concentrate for solution for infusion (Trodelvy®)	2446	Treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior lines of systemic therapies, at least one of them given for unresectable locally advanced or metastatic disease.	Routinely available in line with national guidance, SMC 2446 https://www.scottishmedicines.org.uk/media/6731/sacituzumab-trodelvy-final-feb-2022-for-website.pdf Updates decision 15/03/22	20/12/2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
sebelipase alfa 2mg/mL concentrate solution (Kanuma®)	2437	Long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency.	Not routinely available as not recommended for use in NHS Scotland, SMC 2437 https://www.scottishmedicines.org.uk/media/6425/sebelipase-alfa-kanuma-non-sub-final-october-2021-for-website.pdf	16/11/2021
selpercatinib 40mg, 80mg hard capsules (Retsevmo®)	2370	As monotherapy - for the treatment of adults with advanced RET fusion-positive thyroid cancer who require systemic therapy following prior treatment with sorafenib and/or lenvatinib. - for the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC) who require systemic therapy following prior treatment with cabozantinib and/or vandetanib.	Routinely available in line with national guidance, on an interim basis subject to ongoing evaluation and future reassessment, SMC 2370 https://www.scottishmedicines.org.uk/media/6247/selpercatinib-retsevmo-final-august-2021-for-website.pdf Updates decision 21/09/21	15/02/2022
selpercatinib 40mg, 80mg hard capsules (Retsevmo®)	2371	As monotherapy for the treatment of adults with advanced RET fusion-positive non-small cell lung cancer (NSCLC) who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.	Not routinely available as not recommended for use in NHS Scotland, SMC 2371 https://www.scottishmedicines.org.uk/media/6426/selpercatinib-retsevmo-final-october-2021-for-website.pdf	16/11/2021
solriamfetol 75mg, 150mg film-coated tablets (Sunosi®)	2419	To improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP).	Not routinely available as not recommended for use in NHS Scotland, SMC 2419 https://www.scottishmedicines.org.uk/media/6732/solriamfetol-sunosi-final-feb-2022-for-website.pdf	15/03/2022
sotorasib 120mg film-coated tablets (Lumykras®)	2443	As monotherapy for the treatment of adult patients with KRAS G12C-mutated, locally advanced or metastatic, non-small cell lung cancer (NSCLC), who have progressed on, or are intolerant to platinum-based chemotherapy and/or anti PD-1/PD-L1 immunotherapy.	Routinely available in line with national guidance, on an interim basis subject to ongoing evaluation and future reassessment, SMC 2443 https://www.scottishmedicines.org.uk/media/6733/sotorasib-lumykras-final-feb-2022-amended-220222-for-website.pdf Updates decision 15/03/22	18/10/2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
standardised allergen extract of pollen from white birch betula verrucosa oral lyosphilisate (Itulazax 12 SQ-Bet®)	2471	In adult patients for the treatment of moderate-to-severe allergic rhinitis and/or conjunctivitis induced by pollen from the birch homologous group. ITULAZAX is indicated in patients with a clinical history of symptoms despite use of symptom-relieving medication and a positive test of sensitisation to a member of the birch homologous group (skin prick test and/or specific IgE).	Not routinely available as not recommended for use in NHS Scotland, SMC 2471 https://www.scottishmedicines.org.uk/media/6735/betula-verrucosa-itulazax-non-sub-final-feb-for-website.pdf	15/03/2022
tirbanibulin 10mg/g ointment (Klisyri®)	2395	Field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults.	Routinely available in line with national guidance, SMC 2395 https://www.scottishmedicines.org.uk/media/6538/tirbanibulin-klisyri-final-november-2021-for-website.pdf Updates decision 21/12/21	15/02/2022
tralokinumab 150mg solution for injection in pre-filled syringe (Adtralza®)	2403	Treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. SMC restriction: patients who have had an inadequate response to an existing systemic immunosuppressant such as ciclosporin, or in whom such treatment is considered unsuitable.	Routinely available in line with national guidance, SMC 2403 https://www.scottishmedicines.org.uk/media/6589/tralokinumab-adtralza-final-december-2021docx-for-website.pdf Updates decision 18/01/22	17/05/2022
trastuzumab deruxtecan 100mg powder for concentrate for solution for infusion (Enhertu®)	2388	As monotherapy for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received two or more prior anti-HER2-based regimens.	Routinely available in line with national guidance, SMC 2388 https://www.scottishmedicines.org.uk/media/6590/trastuzumab-deruxtecan-enhertu-final-december-2021docx-amended-241221docx-for-website.pdf Updates decision 18/01/22	16/08/2022
tucatinib 50mg, 150mg film-coated tablets (Tukysa®)	2398	In combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least two prior anti-HER2 treatment regimens.	Routinely available in line with national guidance, SMC 2398 https://www.scottishmedicines.org.uk/media/6591/tucatinib-tukysa-final-december-2021docx-for-website.pdf Updates decision 18/01/22	16/08/2022

NHS Grampian Formulary Group Decisions for SMC advice published April 2021 to March 2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
upadacitinib 15mg prolonged-release tablets (Rinvoq®)	2361	<p>For the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. Upadacitinib may be used as monotherapy or in combination with methotrexate.</p> <p>SMC restriction: for use in patients with psoriatic arthritis whose disease has not responded adequately to at least two conventional DMARDs (cDMARDs), given either alone or in combination.</p>	<p>Routinely available in line with national guidance, SMC 2361</p> <p>https://www.scottishmedicines.org.uk/media/5944/upadacitinib-rinvoq-abbreviated-final-april-2021docx-for-website.pdf</p> <p>Updates decision 18/05/21</p>	19/10/2021
vericiguat 2.5mg, 5mg, 10mg film-coated tablets (Verquvo®)	2425	<p>Treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy.</p>	<p>Not routinely available as not recommended for use in NHS Scotland, SMC 2425</p> <p>https://www.scottishmedicines.org.uk/media/6339/vericiguat-verquvo-non-submission-final-sept-2021-for-website.pdf</p>	19/10/2021
vigabatrin 100mg, 500mg soluble tablets (Kigabeq®)	2352	<p>In infants and children from 1 month to less than 7 years of age for:</p> <ul style="list-style-type: none"> - treatment in monotherapy of infantile spasms (West's syndrome). - treatment in combination with other antiepileptic medicinal products for patients with resistant partial epilepsy (focal onset seizures) with or without secondary generalisation, that is where all other appropriate medicinal product combinations have proved inadequate or have not been tolerated. <p>SMC restriction: patients in whom other formulations of vigabatrin are not suitable.</p>	<p>Not routinely available as the ADTC is waiting for further advice from local clinical experts</p>	15/06/2021